Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP8 | P40818 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 2/20 | 0.33 |
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.33 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23700104 | 0.85 | USP8 (0.40) | USP8RECQLPOLBTSHRMAPK1 | |
| SCHEMBL620504 | 0.79 | USP8 (0.42) | USP8RECQLKDM4EMAP4K1 | |
| SCHEMBL20095136 | 0.79 | USP8 (0.39) | USP8RECQLPOLBGAAHPGD | |
| SCHEMBL1617515 | 0.77 | MAPT (0.37) | USP8RECQLPOLBGAAHPGD | |
| SCHEMBL20106531 | 0.77 | CHEK1 (0.40) | USP8MAP4K1 | |
| SCHEMBL7576503 | 0.75 | KDM4E (0.34) | RECQLPOLBHPGDKDM4EALDH1A1 | |
| SCHEMBL15233567 | 0.74 | CCR4 (0.38) | RECQLHPGDCCR4SQORKDM4E | |
| SCHEMBL18185851 | 0.74 | MAPK8 (0.43) | USP8MAPK1GAAHPGDMAP4K1 | |
| SCHEMBL10220596 | 0.73 | CHEK1 (0.43) | MAP4K1 | |
| SCHEMBL4497174 | 0.73 | CCR4 (0.37) | RECQLHPGDCYP1A2CYP2C19CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-08-05 | — | — | US | disclosed |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-08-05 | — | — | US | disclosed |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-09 | — | — | US | disclosed |
| US-10905688-B2 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2021-02-02 | — | — | US | disclosed |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-12-08 | — | — | US | disclosed |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-12-08 | — | — | US | disclosed |
| EP-3532064-B1 | COMBINATION TREATMENTS COMPRISING IMIDAZOPYRAZINONES FOR THE TREATMENT OF PSYCHIATRIC AND/OR COGNITIVE DISORDERS | H LUNDBECK AS (DK) | 2020-07-29 | — | — | EP | disclosed |
| US-20190282572-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. LUNDBECKA/S (DK) | 2019-09-19 | — | — | US | disclosed |
| US-20190282571-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | H. LUNDBECK A/S (DK) | 2019-09-19 | — | — | US | disclosed |
| US-20170291903-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2017-10-12 | — | — | US | disclosed |
| US-20170291903-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2017-10-12 | — | — | US | disclosed |
| US-20170173018-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS PDE9 INHIBITORS | SUNDIA MEDITECH COMPANY, LTD. (CN) | 2017-06-22 | — | — | US | disclosed |
| US-9643970-B2 | Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors | H. LUNDBECK A/S (DK) | 2017-05-09 | — | — | US | disclosed |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | US | disclosed |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | US | disclosed |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | US | disclosed |
| WO-2016174188-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016174188-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | WO | disclosed |
| US-20150274736-A1 | PDE9i with imidazo pyrazinone backbone | SUNDIA MEDITECH COMPANY, LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282571-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | PDE12, PDE1B, PDE1A | USP8 2555/4885RECQL 360/4885POLB 1527/4885 |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | PDE12, PDE4A, PDE5A | USP8 2264/4885RECQL 1404/4885POLB 2748/4885 |
| US-10858362-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | USP8 2264/4885RECQL 1404/4885POLB 2748/4885 |
| US-20150274736-A1 | PDE9i with imidazo pyrazinone backbone | PDE9A, PDE5A, PDE12 | USP8 2314/4885RECQL 768/4885POLB 1449/4885 |
| US-20170173018-A1 | SUBSTITUTED IMIDAZO[1,5-a]PYRAZINES AS PDE9 INHIBITORS | PDE9A, PDE12, PDE5A | USP8 2291/4885RECQL 1199/4885POLB 1981/4885 |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | PDE12, PDE4A, PDE5A | USP8 2264/4885RECQL 1404/4885POLB 2748/4885 |
| US-20170291903-A1 | Imidazopyrazinones as PDE1 Inhibitors | PDE12, PDE4A, PDE5A | USP8 2264/4885RECQL 1404/4885POLB 2748/4885 |
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | USP8 2264/4885RECQL 1404/4885POLB 2748/4885 |
| US-10912773-B2 | Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors | PDE5A, PDE3A, PDE12 | USP8 3404/4885RECQL 216/4885POLB 1167/4885 |
| US-10905688-B2 | Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors | PDE1A, PDE12, PDE1B | USP8 2915/4885RECQL 711/4885POLB 1270/4885 |
| US-20190282572-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES | PDE12, PDE4A, PDE1A | USP8 3007/4885RECQL 172/4885POLB 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.